DK2548578T3 - Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme - Google Patents
Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdommeInfo
- Publication number
- DK2548578T3 DK2548578T3 DK12178894.7T DK12178894T DK2548578T3 DK 2548578 T3 DK2548578 T3 DK 2548578T3 DK 12178894 T DK12178894 T DK 12178894T DK 2548578 T3 DK2548578 T3 DK 2548578T3
- Authority
- DK
- Denmark
- Prior art keywords
- vegf
- targeting
- regulation
- fatty acid
- human diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80154906P | 2006-05-17 | 2006-05-17 | |
EP07794959.2A EP2018184B1 (en) | 2006-05-17 | 2007-05-17 | Anti-VEGF-B antibody for the treatment or prophylaxis of diabetes type II or metabolic syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2548578T3 true DK2548578T3 (da) | 2014-10-06 |
Family
ID=38723820
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12178894.7T DK2548578T3 (da) | 2006-05-17 | 2007-05-17 | Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme |
DK07794959.2T DK2018184T3 (da) | 2006-05-17 | 2007-05-17 | Anti-vegf-b-antistof til behandling eller forebyggende behandling af type 2-diabetes eller metabolisk syndrom |
DK12178908.5T DK2548579T3 (da) | 2006-05-17 | 2007-05-17 | Målretning af vegf-b-regulering af fedtsyretransportere med henblik på at modulere menneskesygdomme |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07794959.2T DK2018184T3 (da) | 2006-05-17 | 2007-05-17 | Anti-vegf-b-antistof til behandling eller forebyggende behandling af type 2-diabetes eller metabolisk syndrom |
DK12178908.5T DK2548579T3 (da) | 2006-05-17 | 2007-05-17 | Målretning af vegf-b-regulering af fedtsyretransportere med henblik på at modulere menneskesygdomme |
Country Status (7)
Country | Link |
---|---|
US (3) | US8114399B2 (da) |
EP (3) | EP2548579B1 (da) |
AU (1) | AU2007254243B2 (da) |
DK (3) | DK2548578T3 (da) |
ES (2) | ES2429225T3 (da) |
PL (2) | PL2548578T3 (da) |
WO (1) | WO2007136679A2 (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7981863B2 (en) * | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
WO2007136679A2 (en) | 2006-05-17 | 2007-11-29 | Ludwig Institute For Cancer Research | Targeting vegf-b regulation of fatty acid transporters to modulate human diseases |
KR20220008944A (ko) | 2008-01-18 | 2022-01-21 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법 |
WO2009126698A2 (en) * | 2008-04-09 | 2009-10-15 | Ludwig Institute For Cancer Research | Regulation of fatty acid transporters |
KR20130041962A (ko) | 2010-07-23 | 2013-04-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법 |
CA2806293A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
MX361944B (es) | 2010-07-23 | 2018-12-19 | President And Fellows Of Harvard College Star | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales. |
AU2011280936A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
EP2714063B1 (en) * | 2011-06-01 | 2017-12-27 | Universität Heidelberg | Vegfr2/3-activating agent for use in the treatment of cognitive dysfunctions |
US9415090B2 (en) | 2011-06-01 | 2016-08-16 | Universität Heidelberg | VEGF-D/VEGFR2/3-mediated regulation of dendrites |
EP2529745A1 (en) * | 2011-06-01 | 2012-12-05 | Universität Heidelberg | VEGF-D/VEGFR mediated regulation of dendrites |
US20130331330A1 (en) * | 2012-06-08 | 2013-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase |
CA2876731A1 (en) | 2012-06-15 | 2013-12-19 | Harry Stylli | Methods of detecting diseases or conditions |
KR20150035818A (ko) | 2012-06-15 | 2015-04-07 | 해리 스타일리 | 순환 병든 세포를 사용하여 질환 또는 병태를 검출하는 방법 |
US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
EP4202441A3 (en) | 2013-03-09 | 2023-07-26 | Immunis.AI, Inc. | Gene expression profile in macrophages for the diagnosis of cancer |
WO2016040843A1 (en) | 2014-09-11 | 2016-03-17 | Harry Stylli | Methods of detecting prostate cancer |
DK3220952T3 (da) | 2014-11-17 | 2021-07-19 | Csl Ltd | Fremgangsmåde til behandling eller forebyggelse af slagtilfælde |
US20190119369A1 (en) * | 2016-04-21 | 2019-04-25 | Csl Limited | Method of treating or preventing liver conditions |
CN107537026A (zh) * | 2017-08-31 | 2018-01-05 | 中山大学中山眼科中心 | Vegf‑b的应用 |
EP3852803A4 (en) * | 2018-09-18 | 2022-06-15 | CSL Limited | METHOD OF TREATMENT OF CACHECTIC DISORDERS |
US20230174633A1 (en) * | 2020-03-30 | 2023-06-08 | Memorial Sloan Kettering Cancer Center | Methods and compositions for modulating lipid storage in adipose tissue |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5244805A (en) | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
IT1242149B (it) | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
US5849571A (en) | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
US5879934A (en) | 1992-07-31 | 1999-03-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US5661033A (en) | 1992-11-25 | 1997-08-26 | The Board Of Trustees Of The Leland Stanford Junior University | Gene transfer using herpes virus vectors as a tool for neuroprotection |
DE4311651A1 (de) | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen |
US5834441A (en) | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
DK0733103T3 (da) | 1993-11-09 | 2004-07-12 | Univ Johns Hopkins | Fremstilling af höje titre af rekombinante AAV vektorer |
FR2716682B1 (fr) | 1994-01-28 | 1996-04-26 | Centre Nat Rech Scient | Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations. |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5686278A (en) | 1994-03-25 | 1997-11-11 | Indiana University Foundation | Methods for enhanced retrovirus-mediated gene transfer |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
WO1998033917A1 (en) | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
US6221839B1 (en) | 1994-11-14 | 2001-04-24 | Helsinki University Licensing Ltd. Oy | FIt4 ligand and methods of use |
US5723750A (en) | 1995-01-12 | 1998-03-03 | Vanderbilt University | Transgenic plants expressing disassembly deficient viral coat proteins |
US5928939A (en) * | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
FR2732357B1 (fr) | 1995-03-31 | 1997-04-30 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose |
US5830725A (en) | 1995-04-28 | 1998-11-03 | The Board Of Trustees For The Leland Stanford Junior University | Rapid, stable high-titre production of recombing retrovirus |
US5773289A (en) | 1995-06-06 | 1998-06-30 | University Of Pittsburgh | AAV directed targeted integration |
US5622856A (en) | 1995-08-03 | 1997-04-22 | Avigen | High efficiency helper system for AAV vector production |
US5830727A (en) | 1995-11-18 | 1998-11-03 | Human Gene Therapy Research Institute | Herpes simplex virus amplicon mini-vector gene transfer system |
US5770414A (en) | 1996-02-20 | 1998-06-23 | The Regents Of The University Of California | Regulatable retrovirus system for genetic modification of cells |
DK2107109T3 (da) | 1996-08-23 | 2012-09-24 | Vegenics Pty Ltd | Rekombinant vaskulær endotelcelle-vækstfaktor D (VEGF-D) |
WO1998008858A1 (en) | 1996-08-26 | 1998-03-05 | Hybridon, Inc. | Improved reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages |
EP0960334A1 (en) | 1996-12-20 | 1999-12-01 | Ludwig Institute For Cancer Research | Vegf-b/receptor complex and uses thereof |
WO1999047677A2 (en) | 1998-03-17 | 1999-09-23 | Genentech, Inc. | Polypeptides homologous to vegf and bmp1 |
US6278039B1 (en) | 1997-05-28 | 2001-08-21 | Axys Pharmaceuticals, Inc. | C. elegans deletion mutants |
US6232463B1 (en) | 1997-10-09 | 2001-05-15 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US6251588B1 (en) | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
CA2325399A1 (en) | 1998-03-23 | 1999-09-30 | Invitrogen Corporation | Modified nucleotides and methods useful for nucleic acid sequencing |
US6127121A (en) | 1998-04-03 | 2000-10-03 | Epoch Pharmaceuticals, Inc. | Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination |
US6537806B1 (en) | 1998-06-02 | 2003-03-25 | University Of Washington | Compositions and methods for treating diabetes |
KR100284739B1 (ko) * | 1998-09-25 | 2001-05-02 | 윤종용 | 불휘발성메모리장치제조방법 |
EP1123408A1 (en) | 1998-09-30 | 2001-08-16 | Ludwig Institute For Cancer Research | Platelet-derived growth factor c, dna coding therefor, and uses thereof |
WO2000025805A1 (en) | 1998-11-02 | 2000-05-11 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2 |
EP1129110B1 (en) | 1998-11-10 | 2009-12-09 | Ludwig Institute For Cancer Research | Platelet-derived growth factor d, dna coding therefor, and uses thereof |
AUPQ592100A0 (en) * | 2000-02-29 | 2000-03-23 | Council Of The Queensland Institute Of Medical Research, The | A method of treatment and prophylaxis |
IL151781A0 (en) | 2000-03-16 | 2003-04-10 | Genetica Inc | Methods and compositions for rna interference |
WO2002007514A2 (en) | 2000-07-26 | 2002-01-31 | Ludwig Institute Of Cancer Research | Glycosylated vegf-b and method for increasing the amount of soluble vegf-b |
US20070050857A1 (en) | 2001-02-28 | 2007-03-01 | Hayward Nick K | Method of treatment and prophylaxis |
JP2005505510A (ja) | 2001-06-20 | 2005-02-24 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Vegf−bによる血管新生の刺激 |
WO2004002427A2 (en) * | 2002-06-27 | 2004-01-08 | The General Hospital Corporation | Methods for the treatment or prevention of obesity |
US20050214280A1 (en) | 2004-03-02 | 2005-09-29 | Ludwig Institute For Cancer Research | Method for inhibiting tumor formation and growth |
US20050282233A1 (en) | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
WO2005087808A2 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Growth factor binding constructs materials and methods |
WO2007136679A2 (en) | 2006-05-17 | 2007-11-29 | Ludwig Institute For Cancer Research | Targeting vegf-b regulation of fatty acid transporters to modulate human diseases |
US9925869B2 (en) | 2014-12-17 | 2018-03-27 | Magna Powertrain Of America, Inc. | Two-speed transfer case with non-synchronized range shift mechanism and on-the-move range shift control system |
-
2007
- 2007-05-17 WO PCT/US2007/011788 patent/WO2007136679A2/en active Application Filing
- 2007-05-17 PL PL12178894T patent/PL2548578T3/pl unknown
- 2007-05-17 DK DK12178894.7T patent/DK2548578T3/da active
- 2007-05-17 ES ES07794959T patent/ES2429225T3/es active Active
- 2007-05-17 US US12/299,672 patent/US8114399B2/en not_active Expired - Fee Related
- 2007-05-17 EP EP12178908.5A patent/EP2548579B1/en not_active Not-in-force
- 2007-05-17 EP EP07794959.2A patent/EP2018184B1/en active Active
- 2007-05-17 AU AU2007254243A patent/AU2007254243B2/en not_active Ceased
- 2007-05-17 ES ES12178894.7T patent/ES2497641T3/es active Active
- 2007-05-17 EP EP12178894.7A patent/EP2548578B1/en active Active
- 2007-05-17 DK DK07794959.2T patent/DK2018184T3/da active
- 2007-05-17 PL PL07794959T patent/PL2018184T3/pl unknown
- 2007-05-17 DK DK12178908.5T patent/DK2548579T3/da active
-
2012
- 2012-01-04 US US13/343,493 patent/US8383112B2/en active Active
-
2013
- 2013-01-18 US US13/744,728 patent/US9078877B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK2018184T3 (da) | 2013-10-28 |
WO2007136679A2 (en) | 2007-11-29 |
US8383112B2 (en) | 2013-02-26 |
EP2548578A1 (en) | 2013-01-23 |
EP2018184A4 (en) | 2010-05-05 |
PL2548578T3 (pl) | 2014-12-31 |
AU2007254243A1 (en) | 2007-11-29 |
WO2007136679A3 (en) | 2008-12-11 |
ES2497641T3 (es) | 2014-09-23 |
US20130156757A1 (en) | 2013-06-20 |
EP2548579A1 (en) | 2013-01-23 |
EP2018184B1 (en) | 2013-09-11 |
EP2548579B1 (en) | 2015-09-02 |
US9078877B2 (en) | 2015-07-14 |
EP2548578B1 (en) | 2014-08-20 |
ES2429225T3 (es) | 2013-11-13 |
AU2007254243B2 (en) | 2013-06-13 |
US20090324611A1 (en) | 2009-12-31 |
PL2018184T3 (pl) | 2013-12-31 |
US8114399B2 (en) | 2012-02-14 |
US20120114642A1 (en) | 2012-05-10 |
EP2018184A2 (en) | 2009-01-28 |
DK2548579T3 (da) | 2015-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2548578T3 (da) | Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme | |
BRPI0720046A2 (pt) | Composição de suplemento nutricional para tratamento de doenças oculares | |
DK2474321T3 (da) | Sammensætninger til behandling af collagenmedierede sygdomme | |
DK1937633T3 (da) | Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme | |
DK2285808T3 (da) | Spiroindolderivater til behandling af parasitsygdomme | |
DK1874781T3 (da) | Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme | |
BRPI0908026A2 (pt) | Métodos para o tratamento de doenças do intestino | |
BRPI0911780A2 (pt) | compostos regulados de hormônio de crescimento humano recombinante | |
DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
HK1151983A1 (en) | Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling 3 3 | |
DK2056807T3 (da) | Behandling af inflammatoriske sygdomme | |
DK2056842T3 (da) | Modificeret galactosylceramid til behandling af cancerøse sygdomme | |
DK2627345T3 (da) | Formuleringer til behandling af sygdomme i de øvre luftveje | |
DK3338777T3 (da) | Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme | |
BRPI0921947A2 (pt) | formulações de proteína terapêutica | |
IL195063A0 (en) | Use of tetramic acid derivatives for insect control | |
DK2117565T3 (da) | Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme | |
FI20095600A (fi) | Koostumus ihosairauksien hoitoa varten | |
BRPI0917210A2 (pt) | exoterma controlada de formulações de cianocrilato | |
DK2099446T3 (da) | Fremgangsmåde til behandling af inflammatorisk tarmsygdom | |
DK2296651T3 (da) | 5-hydroxymethyl-oxazolidin-2-on-derivater til behandling af bakterielle intestinale sygdomme | |
DK2142032T3 (da) | Kunstige negle indbefattende påføringsflig | |
DE102009018133A8 (de) | Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen | |
BRPI0815597A2 (pt) | Formulações de emulsões com derivado de pirazolona | |
BR112013007635A2 (pt) | ''composto selecionados da fórmula 1, composição fungicida e método para controlar doenças de planta'' |